Physician profile
Stephen H Carson
NPI 1780719872
$1,602.74
in general payments reported to CMS, 2019-2025
15 companies · $116 in 2025
The $116 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $109 · 2021: $250 · 2022: $201 · 2023: $354 · 2024: $393 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $421.02 | 2019-2024 | |
| Sanofi Pasteur INC. | $374.46 | 2019-2025 | |
| Cranial Technologies, INC | $180.57 | 2021-2025 | Doc Band |
| Glaxosmithkline, LLC. | $109.34 | 2019-2024 | Bexsero |
| Seqirus USA INC | $91.56 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Welch Allyn | $85.06 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $65.07 | 2023-2024 | Flumist Quadrivalent |
| Verrica Pharmaceuticals INC. | $64.54 | 2023-2024 | Ycanth |
| Alexion Pharmaceuticals, INC. | $61.28 | 2019-2024 | Koselugo |
| Sanofi-Aventis U.S. LLC | $44.96 | 2024 | |
| Kaleo, INC. | $34.84 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $22.18 | 2025 | Neffy |
| Mylan Pharmaceuticals INC. | $19.25 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.28 | 2023 | |
| Ironshore Pharmaceuticals INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.